Sublingual vs Oral (Swallowed) Ketamine: Absorption and Efficacy Differences

Overview

Among non-intravenous ketamine formulations, the distinction between sublingual and oral (swallowed) administration is one of the most clinically relevant yet frequently misunderstood differences in ketamine therapeutics. Though both routes ultimately deliver ketamine through the gastrointestinal and oral mucosa, the pharmacokinetic profiles differ meaningfully due to the extent of first-pass hepatic metabolism each route avoids or undergoes.

Sublingual ketamine -- typically formulated as rapidly dissolving tablets (RDTs), troches, or liquid solutions held under the tongue -- is absorbed partially through the highly vascularized sublingual mucosa directly into systemic circulation, bypassing hepatic first-pass metabolism for the fraction absorbed transmucosally. Oral (swallowed) ketamine -- delivered as capsules, tablets, or solutions that are swallowed and absorbed through the gastrointestinal tract -- undergoes extensive first-pass metabolism before reaching systemic circulation.

Understanding these differences helps clinicians optimize sublingual and oral protocol design and helps patients understand why administration technique matters.

First-Pass Metabolism and Bioavailability

When ketamine is swallowed, it is absorbed through the gastrointestinal tract and transported via the portal vein to the liver, where CYP3A4 and CYP2B6 enzymes convert approximately 75-83% of the dose to norketamine and other metabolites before it reaches systemic circulation. This first-pass effect is the dominant factor limiting oral ketamine's bioavailability to approximately 17-24% (Peltoniemi et al., 2016).

Sublingual administration partially circumvents this pathway. The sublingual mucosa is thin, highly vascularized, and drains directly into the internal jugular vein rather than the portal system. Ketamine absorbed through this mucosa enters systemic circulation without passing through the liver first. Studies by Rolan et al. (2014) and others have measured sublingual ketamine bioavailability at approximately 25-30%, representing a meaningful improvement over swallowed administration.

Clinical: The bioavailability advantage of sublingual over swallowed administration depends critically on administration technique. Patients must hold the ketamine preparation under the tongue for a minimum of 10-15 minutes to allow adequate transmucosal absorption. Swallowing the preparation prematurely converts the sublingual route into an oral one, negating the bioavailability advantage. Patient education on proper technique is essential.

However, it is important to note that sublingual administration is never purely transmucosal. Even with optimal technique, patients inevitably swallow saliva containing dissolved ketamine, and a significant fraction of the dose ends up being absorbed through the GI tract. The actual sublingual bioavailability therefore represents a composite of transmucosal absorption (higher bioavailability, faster onset) and swallowed GI absorption (lower bioavailability, delayed onset, more norketamine production).

Onset of Action and Pharmacokinetic Profile

Sublingual ketamine onset occurs within 10-20 minutes, with peak plasma concentration at 20-30 minutes. Swallowed formulations require 30-60 minutes for onset and 45-90 minutes to peak. This faster onset means sublingual treatment sessions can be somewhat shorter (approximately 1-1.5 hours) compared with oral sessions (1.5-2.5 hours). The sublingual pharmacokinetic profile -- sharp rise, moderate peak, gradual decline -- more closely resembles a scaled-down IV ketamine profile, whereas oral ketamine produces a flatter, more prolonged curve.

Dosing Strategies

Sublingual Dosing

Sublingual ketamine is most commonly prescribed as:

• Troches (lozenges): Compounded ketamine in a flavored base, held in the mouth and allowed to dissolve slowly while positioning dissolved material under the tongue
• Rapidly dissolving tablets: Formulated to disintegrate quickly in the sublingual space
• Liquid solutions: Compounded ketamine solution (typically 100-200 mg/mL) held under the tongue

Common sublingual dose ranges for depression:

These doses are higher than IV doses (0.5 mg/kg = 35 mg for a 70-kg patient) because of the approximately 25-30% bioavailability, meaning only about one-quarter to one-third of the sublingual dose reaches systemic circulation. The weight-based dosing guidelines for sublingual administration typically use 1.0-4.0 mg/kg as the working range.

Oral (Swallowed) Dosing

Oral ketamine is typically prescribed as:

• Compounded capsules: Standard gelatin capsules containing powdered ketamine
• Oral solutions: Liquid formulations for flexible dosing
• Compounded tablets: Less common, used in some research protocols

Because oral bioavailability is lower than sublingual, equivalent systemic exposure requires modestly higher doses:

The higher doses required for oral administration raise questions about gastrointestinal tolerability, as nausea is a common side effect that may be dose-dependent and exacerbated by higher oral doses.

Taste and Tolerability

One of the most significant practical differences between sublingual and swallowed ketamine is the taste experience. Ketamine has an intensely bitter, unpleasant taste that is a well-known barrier to sublingual compliance. The sublingual route requires patients to hold a bitter-tasting preparation in their mouth for 10-15 minutes, which some find intolerable.

Compounding pharmacies address this with flavoring agents, sweeteners, and troche formulations that partially mask bitterness. Despite these efforts, an estimated 10-20% of patients cannot tolerate sublingual administration and prefer to swallow the preparation. Swallowed ketamine in capsule form completely eliminates the taste issue, representing a genuine advantage for taste-sensitive patients.

Clinical: For patients who struggle with the sublingual taste but want to maximize bioavailability, a practical compromise is the "swish and spit, then swallow" technique -- holding the preparation sublingually for as long as tolerable (even 5-7 minutes provides some transmucosal absorption), then swallowing the remainder. This hybrid approach captures partial sublingual absorption while limiting taste exposure time. However, bioavailability with shortened holding times will fall between the sublingual and oral values.

Clinical Outcomes: Head-to-Head Data

Direct head-to-head comparisons of sublingual versus swallowed ketamine for depression are exceedingly rare. The available indirect evidence suggests both routes produce clinically meaningful antidepressant effects in patients with treatment-resistant depression, with the modest bioavailability difference likely translating into modest efficacy differences. Individual patient factors -- CYP enzyme polymorphisms, hepatic function, and administration technique -- likely contribute more to outcome variability than the route difference itself.

Lara et al. (2013), in Journal of Affective Disorders, reported significant antidepressant effects with sublingual ketamine (0.5 mg/kg) in treatment-resistant bipolar depression.

Practical Recommendations

Choose sublingual when:

• Maximizing bioavailability from a non-IV route is a priority
• The patient can tolerate the taste and 10-15 minute holding period
• Faster onset within the session is desired
• Lower doses (and potentially fewer GI side effects) are preferred

Choose oral (swallowed) when:

• Taste is a significant barrier to compliance
• The patient prefers capsule formulations
• Simplicity of administration is valued (swallow and wait)
• The patient cannot physically hold material under the tongue (e.g., oral pathology)

For either route:

• Begin with supervised in-clinic sessions to establish tolerability and response
• Educate patients thoroughly on proper sublingual technique if that route is chosen
• Use validated outcome measures to track response and guide dose adjustments
• Monitor for common side effects and ensure contraindication screening is complete

References

• Lara DR, Bisol LW, Munari LR (2013). Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. International Journal of Neuropsychopharmacology, 16(9), 2111-2117. PubMed
• Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI (2016). Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy. Clinical Pharmacokinetics, 55(9), 1059-1077. PubMed
• Rolan P, Lim S, Sunderland V, Liu Y, Molnar V (2014). The absolute bioavailability of racemic ketamine from a novel sublingual formulation. British Journal of Clinical Pharmacology, 77(6), 1011-1016. PubMed
• Zanos P, Moaddel R, Morris PJ, et al. (2016). NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature, 533(7604), 481-486. PubMed
• National Institutes of Health (NIH). Ketamine. NIH DailyMed